Analyst consensus rating
Biogen Analyst Rating: Buy
Direct answer
Biogen's consensus rating is Buy.
32 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $264.23.
Forecast evidence checked November 2, 2026.
Get free Biogen email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $253.62
- Average price target
- $264.23
- High price target
- $325.00
- Low price target
- $175.00
- Low target gap
- -31%
- Target upside
- +4.2%
- High target gap
- +28.1%
- Target range width
- 59.1%
- Consensus rating
- Buy
- Analysts
- 32
- Evidence date
- November 2, 2026
- Valid through
- November 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Biogen?
Biogen has a verified Buy consensus. The same dataset has an average price target of $264.23.
How far are Biogen's low and high targets from the recorded price?
The low target implies -31%, while the high target implies +28.1%.
How many analysts are included in Biogen's consensus?
The verified consensus includes 32 analysts.
How is Biogen's target upside or downside calculated?
The average target of $264.23 is divided by the recorded price of $253.62, then one is subtracted to produce +4.2%. This does not guarantee a future return.
When was Biogen's analyst forecast verified?
The data was verified on 2026-11-02. The dataset is valid through 2026-11-09.